GGrantIndex
← Leaderboards

June-Wha Rhee

Stanford University

$1,627,821
Attributed
$1,627,821
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $698K · FY201625
$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$1,627,821 · 3

By mechanism

K08$760,408 · 1
R01$697,952 · 1
F32$169,461 · 1

Top collaborators

No co-investigators on record.

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Phenotype

Research focus

PhenotypePreventCardiovascular SystemCellsCalciumMolecularCell LineInduced Pluripotent Stem CellCardiacMuscle CellsTherapeutic TargetResearch PersonnelCardiac MyocytesPathogenesisSymptomsGenotypeMedicineAffectGenerationsTechnologyLeadClinicMolecular TargetMouse Model

Grant awards (10)

Novel mechanisms and therapeutics for Tyrosine Kinase Inhibitor-induced Cardiotoxicity$697,952
R01 · FY2025 · HL · contact PI
Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytes$90,326
K08 · FY2024 · HL · contact PI
Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytes$75,600
K08 · FY2024 · HL · contact PI
Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytes$137,160
K08 · FY2023 · HL · contact PI
Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytes$137,160
K08 · FY2022 · HL · contact PI
Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytes$153,626
K08 · FY2021 · HL · contact PI
Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytes$166,536
K08 · FY2020 · HL · contact PI
The use of human induced pluripotent stem cell-derived cardiomyocytes to describe the role of α-Tropomyosin mutations in hypertrophic cardiomyopathy$34,539
F32 · FY2019 · HL · contact PI
The use of human induced pluripotent stem cell-derived cardiomyocytes to describe the role of α-Tropomyosin mutations in hypertrophic cardiomyopathy$70,145
F32 · FY2018 · HL · contact PI
The use of human induced pluripotent stem cell-derived cardiomyocytes to describe the role of α-Tropomyosin mutations in hypertrophic cardiomyopathy$64,777
F32 · FY2016 · HL · contact PI